Sun Pharma launches lipid disorders drug Ezallor Sprinkle™ in the U.S.
Category: #health  By Pankaj Singh  Date: 2019-07-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sun Pharma launches lipid disorders drug Ezallor Sprinkle™ in the U.S.

Ezallor Sprinkle™ (rosuvastatin) capsules can be indicated for three lipid disorders in conjunction with patient’s diet.

Indian pharma giant, Sun Pharmaceutical Industries Ltd. has recently announced the U.S. launch of Ezallor Sprinkle™ (rosuvastatin) capsules, a drug designed specifically to treat patients with elevated lipid disorders.

According to sources, Ezallor Sprinkle is indicated as an adjunct to diet for treating adults with hypertriglyceridemia, primary dysbetalipoproteinemia (type III hyperlipoproteinemia), and other lipid-lowering treatments like LDL apheresis. It also acts as a monotherapy to lower LDL-C, total cholesterol, and ApoB in patients with homozygous familial hypercholesterolemia.

Speaking on the launch, Abhay Gandhi, CEO, North America, Sun Pharma, said that their firm, with Ezallor Sprinkle, will continue on its commitment to provide a portfolio of alternative formulation products that address the needs of patients facing difficulty in swallowing, which is particularly prevalent among residents in long-term care facilities who cannot swallow.

He said that these patients often encounter more medicinal errors and problems with medication administration compared to long-term care residents who don’t face such swallowing difficulties.

Commenting on the issue, Dr. Chris Chappel, Certified Medical Director, Chappel Group Research & Chappel Senior Care, said that the risk of medication errors increases when patients face difficulty in swallowing due to crushing of medicines that should not be crushed, or from residual medication left in crushing devices.

He said that Ezallor Sprinkle’s formulation will help in administering medication for patients with common elevated lipid disorders, especially in the elderly population.

For the record, Ezallor Sprinkle is developed as an extended-release-coated capsule that can be sprinkled over soft food, can be swallowed as whole, or administered through a nasogastric tube to facilitate long-term, once-daily administration.

It combines with Kapspargo Sprinkle™ extended-release tablets as the second drug in the Sun Pharma portfolio designed specifically for individuals in long-term care.

Reports cite that Ezallor Sprinkle is contraindicated in patients with known hypersensitivity to rosuvastatin, which may include pruritus, urticaria, rash, and angioedema. Moreover, in controlled clinical trials, the most common adverse reactions with rosuvastatin were abdominal pain, asthenia, headache, myalgia, and nausea.

Source Credit: https://www.businesswire.com/news/home/20190714005038/en/Sun-Pharma-Launches-Ezallor-Sprinkle-Rosuvastatin-U.S



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...